ROME IV FGIDs | Chapter 17: Design of Treatment Trials for FGIDs

ROME IV FGIDs | Chapter 16: Childhood FGIDs: Child/Adolescent

ROME IV FGIDs | Chapter 18: Development and Validation of the Rome IV Diagnostic Questionnaires

Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013;25:453-457.
Spiegel B, Hays RD, Bolus R, et al. Development of the NIH Patient Reported Outcomes Measurement Information System (PROMIS®) gastrointestinal symptom scales. Am J Gastroenterol 2014;109:1804-1814.
Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-536.
Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-2354.
Macdougall J, Johnston J, Lavins B, et al. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil 2013;25:481-e365.
Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-696.
Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-1740.
Chey WD, Pare P, Viegas A, et al. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008;103:1217-1225.
Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821-828.
Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35:745-767.
Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-e117.
Muller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010;22:991-998, e255.
Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 Suppl 1:S1-35.
Holtmann G, Kutscher SU, Haag S, et al. Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia; a randomized, double-blind placebo-controlled crossover study. Dig Dis Sci 2004;49:672-679.
Gerson C, Gerson M, Awad R, et al. Irritable bowel syndrome: an international study of symptoms in eight countries. Eur J Gastroenterol Hepatol 2008;20:659-667.
Babu J, Kumar S, Babu P, et al. Frequency of lactose malabsorption among healthy southern and northern Indian populations by genetic analysis and lactose hydrogen breath and tolerance tests. Am J Clin Nutr 2010;91:140-146.
Asmawi M, Seppo L, Vapaatalo H, et al. Hypolactasia & lactose intolerance among three ethnic groups in Malaysia. Indian J Med Res 2006;124:697-704.
Spiller RC. Potential biomarkers. Gastroenterology Clin North Am 2011;40:121-139.
Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One 2015;10:e0126438.
Chiarioni G, Whitehead WE, Pezza V, et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006;130:657-664.
Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-924.
Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999;107:91S-97S.
Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996;91:660-673.
Hahn B, Watson M, Yan S, et al. Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci 1998;43:2715-2718.
Palsson OS, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. Am J Gastroenterol 2014;109:1450-1460.
Palsson OS, Baggish JS, Turner MJ, et al. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol 2012;107:286-295.
Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 1992;116:1009-1016.
Whitehead WE. Control groups appropriate for behavioral interventions. Gastroenterology 2004;126:S159-S163.
Camilleri M. Safety concerns about alosetron. Arch Intern Med 2002;162:100-101.
Sackett DL. Bias in analytic research. J Chronic Dis 1979;32:51-63.
Detsky AS, Sackett DL. When was a “negative” clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med 1985;145:709-712.
Jamshidian F, Hubbard AE, Jewell NP. Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomised clinical trials. Stat Methods Med Res 2011;23:293-307.
Miller LE, Stewart ME. The blind leading the blind: use and misuse of blinding in randomized controlled trials. Contemp Clin Trials 2011;32:240-243.
Spilker B. External influences on protocol design. Epilepsy Res Suppl 1993;10:115-124.
Govani SM, Higgins PD. How to read a clinical trial paper: a lesson in basic trial statistics. Gastroenterol Hepatol (N Y) 2012;8:241-248.
Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry 2000;31:73-86.
Altman DG. Randomisation. BMJ 1991;302:1481-1482.
Chalmers TC, Celano P, Sacks HS, et al. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309:1358-1361.
Altman DG. Comparability of randomised groups. The Statistician 1985;34:125-136.
Spilker B. How to improve the quality of clinical trials and their publications. Med Clin (Barc) 1992;98:303-304.
Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-786.
Tinmouth JM, Steele LS, Tomlinson G, et al. Are claims of equivalency in digestive diseases trials supported by the evidence? Gastroenterology 2004;126:1700-1710.
Temple RJ. When are clinical trials of a given agent vs. placebo no longer appropriate or feasible? Control Clin Trials 1997;18:613-620; discussion 661-666.
Manheimer E, Wieland LS, Cheng K, et al. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2012;107:835-847; quiz 848.
Gensini GF, Conti AA, Conti A. Past and present of ‘’what will please the lord’’: an updated history of the concept of placebo. Minerva Med 2005;96:121-124.
Thompson WG. Placebos: a review of the placebo response. Am J Gastroenterol 2000;95:1637-1643.
Bernstein CN. Placebos in medicine. Semin Gastrointest Dis 1999;10:3-7.
Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007;13:3425-3429.
Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology 2004;126:1257-1269.
Gallahan WC, Case D, Bloomfeld RS. An analysis of the placebo effect in Crohn’s disease over time. Aliment Pharmacol Ther 2010;31:102-107.
de Craen AJ, Moerman DE, Heisterkamp SH, et al. Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol 1999;48:853-860.
Bland JM, Altman DG. Some examples of regression towards the mean. BMJ 1994;309:780.
Boyce PM, Talley NJ, Balaam B, et al. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003;98:2209-2218.
Vase L, Robinson ME, Verne GN, et al. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003;105:17-25.
Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:237-247.
Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-158.
Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PloS One 2010;5:e15591.
Conboy LA, Wasserman RH, Jacobson EE, et al. Investigating placebo effects in irritable bowel syndrome: a novel research design. Contemp Clin Trials 2006;27:123-134.
Kokkotou E, Conboy LA, Ziogas DC, et al. Serum correlates of the placebo effect in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:285-e281.
Lu CL, Chang FY. Placebo effect in patients with irritable bowel syndrome. J Gastroenterol Hepatol 2011;26 Suppl 3:116-118.
Hall KT, Lembo AJ, Kirsch I, et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PloS One 2012;7:e48135.
Wikipedia. Nocebo. Available at: http://en.wikipedia.org/wiki/Nocebo. Accessed,
Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull 2004;130:324-340.
Kim SE, Kubomoto S, Chua K, et al. “Pre-cebo”: an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials. J Clin Gastroenterol 2012;46:686-690.
Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927-933.
Bachert C, Brostoff J, Scadding GK, et al. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group. Allergy 1998;53:969-975.
Berger VW, Rezvani A, Makarewicz VA. Direct effect on validity of response run-in selection in clinical trials. Control Clin Trials 2003;24:156-166.
Clave P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:432-442.
Woods JR, Williams JG, Tavel M. The two-period crossover design in medical research. Ann Intern Med 1989;110:560-566.
EMA. Guideline on the evaluation of medicinal products for for the treatment of irritable bowel syndrome. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500146176.pdf. Accessed December 8, 2014.
Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32:6-38.
Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med 2013;5:178sr173.
Guyatt G, Sackett D, Taylor DW, et al. Determining optimal therapy—randomized trials in individual patients. N Engl J Med 1986;314:889-892.
Lewis JA. Controlled trials in single subjects. 2. Limitations of use. BMJ 1991;303:175-176.
Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131.
Holroyd KA, O’Donnell FJ, Stensland M, et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA 2001;285:2208-2215.
Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470.
Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 1998;20:438-453.
Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004;126:402-413.
Tack J, Muller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-1713.
Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-1724; quiz p 1725.
Gaylord SA, Palsson OS, Garland EL, et al. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol 2011;106:1678-1688.
Faried M, El Nakeeb A, Youssef M, et al. Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. J Gastrointest Surg 2010;14:1235-1243.
Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 2007;50:428-441.
Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 2007;5:331-338.
Heymen S, Scarlett Y, Jones K, et al. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. Dis Colon Rectum 2009;52:1730-1737.
Norton C, Chelvanayagam S, Wilson-Barnett J, et al. Randomized controlled trial of biofeedback for fecal incontinence. Gastroenterology 2003;125:1320-1329.
Solomon MJ, Pager CK, Rex J, et al. Randomized, controlled trial of biofeedback with anal manometry, transanal ultrasound, or pelvic floor retraining with digital guidance alone in the treatment of mild to moderate fecal incontinence. Dis Colon Rectum 2003;46:703-710.
Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643-650.
Hellstrom PM, Saito YA, Bytzer P, et al. Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. Am J Gastroenterol 2011;106:1299-1307.
Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol 2003;3:28.
Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98:S40-48.
Zacny J, Zamakhshary M, Sketris I, et al. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2005;21:1299-1312.
Fujii Y, Tanaka H, Kawasaki T. A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: a double-blind, randomized, controlled trial. Clin Ther 2003;25:1142-1149.
Hellström PM, Hein J, Bytzer P, et al. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009;29:198-206.
Ducrotte P, Grimaud JC, Dapoigny M, et al. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract 2014;68:245-254.
Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction—a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 2012;35:48-55.
Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165-177.
Cremonini F, Delgado?Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta?analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79-86.
Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006:CD002096.
Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-1712.
Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-721 e714.
Schmulson M, Vargas JA, Lopez-Colombo A, et al. Prevalence and clinical characteristics of the IBS subtypes according to the Rome III criteria in patients from a clinical, multicentric trial. A report from the Mexican IBS Working Group. Rev Gastroenterol Mex 2010;75:427-438.
Su AM, Shih W, Presson AP, et al. Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil 2014;26:36-45.
Yao X, Yang YS, Cui LH, et al. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. J Gastroenterol Hepatol 2012;27:760-765.
Jamali R, Jamali A, Poorrahnama M, et al. Evaluation of health related quality of life in irritable bowel syndrome patients. Health Qual Life Outcomes 2012;10:12.
Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. Dig Dis Sci 2008;53:3191-3200.
U.S. Food and Drug Administration. Guidance for industry irritable bowel syndrome-clinical evaluation of drugs for treatment. Silver Spring, MD: Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), 2012.
Cremonini F, Lembo A. Irritable bowel syndrome subtypes: constipation, diarrhea...and mixed bowel pattern: Tertium datur. Neurogastroenterol Motil 2014;26:1-2.
Stone AA, Shiffman S. Capturing momentary, self-report data: A proposal for reporting guidelines. Ann Behav Med 2002;24:236-243.
Bohn L, Storsrud S, Tornblom H, et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013;108:634-641.
Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome—etiology, prevalence and consequences. Eur J Clin Nutr 2006;60:667-672.
Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 2009;109:1204-1214.
Aller R, de Luis DA, Izaola O, et al. Effects of a high-fiber diet on symptoms of irritable bowel syndrome: a randomized clinical trial. Nutrition 2004;20:735-737.
Yao CK, Gibson PR, Shepherd SJ. Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders. Am J Gastroenterol 2013;108:748-758.
Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146:67-75 e65.
Passariello A, Agricole P, Malfertheiner P. A critical appraisal of probiotics (as drugs or food supplements) in gastrointestinal diseases. Curr Med Res Opin 2014;30:1055-1064.
Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590.
Haller D, Antoine JM, Bengmark S, et al. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J Nutr 2010;140:690S-697S.
Rasquin-Weber A, Hyman PE, Cucchiara S, et al. Childhood functional gastrointestinal disorders. Gut 1999;45 Suppl 2:II60-68.
Hyman PE, Milla PJ, Benninga MA, et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 2006;130:1519-1526.
Chogle A, Sztainberg M, Bass L, et al. Accuracy of pain recall in children. J Pediatr Gastroenterol Nutr 2012;55:288-291.
van Tilburg MA, Squires M, Blois-Martin N, et al. Test of the child/adolescent Rome III criteria: agreement with physician diagnosis and daily symptoms. Neurogastroenterol Motil 2013;25:302-e246.
Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-1632.
Siegel CA. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease. Gastroenterology 2009;137:1880-1882.
Khanna P, Agarwal N, Khanna D, et al. Development of an online library of patient-reported outcome measures in gastroenterology: The GI-PRO database. Am J Gastroenterol 2013;109:234-248.
Burke LB, Kennedy DL, Miskala PH, et al. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther 2008;84:281-283.
Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 2007;45:S22-31.
Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007;45:S3-S11.
Spiegel B, Khanna D, Bolus R, et al. Understanding gastrointestinal distress: a framework for clinical practice. Am J Gastroenterol 2011;106:380-385.
Lackner JM, Gudleski GD, Thakur ER, et al. The impact of physical complaints, social environment, and psychological functioning on IBS patients’ health perceptions: looking beyond GI symptom severity. Am J Gastroenterol 2014;109:224-233.
Spiegel BM, Bolus R, Agarwal N, et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther 2010;32:1275-1291.
Spiegel B, Bolus R, Harris LA, et al. Measuring IBS patient reported outcomes with an abdominal pain numeric rating scale: results from the proof cohort. Aliment Pharmacol Ther 2009;30:1159-1170.
Spiegel BM, Bolus R, Harris L, et al. Characterizing abdominal pain attributes in IBS: guidance for study inclusion criteria and outcome measurement. Aliment Pharmacol Ther 2010;32:1192-1202.
Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005;11:S17-S26.
Reilly MC, Bracco A, Ricci JF, et al. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire—irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther 2004;20:459-467.
Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009;104:1984-1991.
Irwin DE, Varni JW, Yeatts K, et al. Cognitive interviewing methodology in the development of a pediatric item bank: a patient reported outcomes measurement information system (PROMIS) study. Health Qual Life Outcomes 2009;7:3.
Weinland SR, Morris CB, Hu Y, et al. Characterization of episodes of irritable bowel syndrome using ecological momentary assessment. Am J Gastroenterol 2011;106:1813-1820.
Weinland S, Morris CB, Hu YJ, et al. Episodes of irritable bowel syndrome—a quantitative examination of IBS-D, C & M symptoms using ecological momentary assessment. Gastroenterol 2009;136:M1222.
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592.
Kim JK, Park ES. Comparative responsiveness and minimal clinically important differences for idiopathic ulnar impaction syndrome. Clin Orthop Relat Res 2013;471:1406-1411.
Farrar JT, Young JP, Jr., LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
Camilleri M, Mangel AW, Fehnel SE, et al. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007;5:534-540.
Bijkerk CJ, de Wit NJ, Muris JW, et al. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003;98:122-127.
Mangel AW, Hahn BA, Heath AT, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998;26:76-81.
Spiegel B, Camilleri M, Bolus R, et al. Psychometric evaluation of patient reported outcomes in IBS randomized controlled trials: A Rome Foundation working group report. Gastroenterology 2009;137:1944-1953.
Whitehead WE, Palsson OS, Levy RL, et al. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006;101:1057-1065.
Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:197-206.
Lackner JM, Jaccard J, Krasner SS, et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol 2008;6:899-906.
Ameen V, Heath A, Mcsorley D, et al. Global measure of adequate relief predicts clinically important difference in pain and is independent of baseline pain severity in IBS. Gastroenterology 2007;132:A140.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-1551.
Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005;3:717-725.
Spiegel B, Strickland A, Naliboff BD, et al. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008;103:2536-2543.
Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995;40:986-995.
Nyren O, Adami HO, Bates S, et al. Self-rating of pain in nonulcer dyspepsia. A methodological study comparing a new fixed-point scale and the visual analogue scale. J Clin Gastroenterol 1987;9:408-414.
Condon D. Medical manpower—the needs of the community. Ir Med J 1977;70:387-388.
Moayyedi P, Duffett S, Braunholtz D, et al. The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. Aliment Pharmacol Ther 1998;12:1257-1262.
Veldhuyzen van Zanten SJ, Tytgat KM, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993;46:273-279.
Rabeneck L, Wristers K, Goldstein JL, et al. Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am J Gastroenterol 2002;97:32-39.
Talley NJ, Haque M, Wyeth JW, et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther 1999;13:225-235.
Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998:41-49.
Svedlund J, Sjodin I, Dotevall G. GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129-134.
Ang D, Talley NJ, Simren M, et al. Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther 2011;33:634-649.
Stanghellini V. Review article: pain versus discomfort—is differentiation clinically useful? Aliment Pharmacol Ther 2001;15:145-149.
Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005;3:543-552.
Houghton LA, Lea R, Agrawal A, et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006;131:1003-1010.
Sperber AD, Drossman DA, Quigley EM. The global perspective on irritable bowel syndrome: a Rome Foundation–World Gastroenterology Organisation symposium. Am J Gastroenterol 2012;107:1602-1609.
Mansoor LE, Dowse R. Effect of pictograms on readability of patient information materials. Ann Pharmacother 2003;37:1003-1009.
Morrow DG, Hier CM, Menard WE, et al. Icons improve older and younger adults’ comprehension of medication information. J Gerontol B Psychol Sci Soc Sci 1998;53:P240-P254.
Tack J, Carbone F, Holvoet L, et al. The use of pictograms improves symptom evaluation by patients with functional dyspepsia. Aliment Pharmacol Ther 2014;40:523-530.
Whitehead WE, Crowell MD, Bosmajian L, et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990;98:336-340.
Taub E, Cuevas JL, Cook EW 3rd, et al. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dig Dis Sci 1995;40:2647-2655.
Spiegel BM, Gralnek IM, Bolus R, et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004;164:1773-1780.
WHO. Constitution of the World Health Organization: handbook of basic documents, 5th ed. Geneva: Palais des Nations, 1952.
Spiegel B, Bolus R, Harris L, et al. Do IBS patients understand the difference between abdominal pain vs. discomfort? Implications for clinical practice and clinical trial design. Gastroenterology 2010;138:S-379.
Heaton KW, O’Donnell LJ, Braddon FE, et al. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992;102:1962-1967.
Sandler RS, Stewart WF, Liberman JN, et al. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci 2000;45:1166-1171.
Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998;42:690-695.
Jiang X, Locke GR 3rd, Choung RS, et al. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut 2008;57:756-763.
Chang L, Lee OY, Naliboff B, et al. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol 2001;96:3341-3347.
Schmulson M, Chang L. Review article: the treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther 2011;33:1071-1086.
Schmulson M. Pending challenges in functional gastrointestinal disorders. Veracruz: Semana Nacional de Gastroenterología, 2013.
Carruthers HR, Morris J, Tarrier N, et al. Reactivity to images in health and irritable bowel syndrome. Aliment Pharmacol Ther 2010;31:131-142.
Schmulson M. Understanding bloating and distension. Digestive Health Matters. Volume 22: International Foundation for Functional Gastrointestinal Disorders (IFFGD), 2013:3-5.
Spiegel B, Bolus R, Agarwal N, et al. Do patients understand the Bristol Stool Scale? Results of cognitive de-briefing of IBS patients. Gastroenterology 2011;140:S-165.
Lopez-Alvarenga JC, Sobrino-Cossio S, Remes-Troche JM, et al. Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100mg plus simethicone 300mg po bid. Rev Gastroenterol Mex 2013;78:21-27.
Bharucha AE, Zinsmeister AR, Locke GR, et al. Risk factors for fecal incontinence: a population-based study in women. Am J Gastroenterol 2006;101:1305-1312.
Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, June 19-22, 1946; signed on 22 July 1946 by the representatives of 61 states (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on April 7, 1948.
Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-629.
Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000;47:861-869.
Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400-411.
Cook KF, O’Malley KJ, Roddey TS. Dynamic assessment of health outcomes: time to let the CAT out of the bag? Health Serv Res 2005;40:1694-1711.
Chakravarty EF, Bjorner JB, Fries JF. Improving patient reported outcomes using item response theory and computerized adaptive testing. J Rheumatol 2007;34:1426-1431.
Koop A, Mosges R. The use of handheld computers in clinical trials. Control Clin Trials 2002;23:469-480.
Stone AA, Shiffman S, Schwartz JE, et al. Patient compliance with paper and electronic diaries. Control Clin Trials 2003;24:182-199.
Lewis JH. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Safe 2011;34:545-565.
Huerta C, Rivero E, Montoro MA, et al. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther 2011;33:969-978.
Chang L, Kahler KH, Sarawate C, et al. Assessment of potential risk factors associated with ischaemic colitis. Neurogastroenterol Motil 2008;20:36-42.
Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010;105:866-875.
Tong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 2013;6:344-357.
Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-788.
Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991.
Shah E, Kim S, Chong K, et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012;125:381-393.
Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-639.
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-732.
Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012;10:28-55.
Egger M, Juni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA 2001;285:1996-1999.
Huwiler-Muntener K, Juni P, Junker C, et al. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002;287:2801-2804.
Perneger TV. What’s wrong with Bonferroni adjustments. BMJ 1998;316:1236-1238.
DerSimonian R, Charette LJ, McPeek B, et al. Reporting on methods in clinical trials. N Engl J Med 1982;306:1332-1337.
Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986;105:429-435.
Guyatt G, Jaeschke R, Heddle N, et al. Basic statistics for clinicians: 2. Interpreting study results: confidence intervals. CMAJ 1995;152:169-173.
Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 2002;287:2813-2814.
Gore SM, Jones G, Thompson SG. The Lancet’s statistical review process: areas for improvement by authors. Lancet 1992;340:100-102.
Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003;138:644-650.
Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
Smith DG, Clemens J, Crede W, et al. Impact of multiple comparisons in randomized clinical trials. Am J Med 1987;83:545-550.
Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-694.
Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-1069.
Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 1995;311:1145-1148.
Reed JF, 3rd, Slaichert W. Statistical proof in inconclusive ‘negative’ trials. Arch Intern Med 1981;141:1307-1310.
Schor S. Statistical proof in inconclusive ‘negative’ trials. Arch Intern Med 1981;141:1263-1264.
Freiman JA, Chalmers TC, Smith H, Jr., et al. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 “negative” trials. N Engl J Med 1978;299:690-694.
Makuch RW, Johnson MF. Some issues in the design and interpretation of ‘negative’ clinical studies. Arch Intern Med 1986;146:986-989.
Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med 1985;4:521-526.
DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet 1999;354:1983-1988.
Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 1987;43:213-223.
Pocock SJ. When to stop a clinical trial. BMJ 1992;305:235-240.
Chow SC. Adaptive clinical trial design. Ann Rev Med 2014;65:405-415.
Cook T, DeMets DL. Review of draft FDA adaptive design guidance. J Biopharm Stat 2010;20:1132-1142.
Chow SC, Chang M, Pong A. Statistical consideration of adaptive methods in clinical development. J Biopharm Stat 2005;15:575-591.
Pocock SJ. The pros and cons of noninferiority trials. Fundam Clin Pharmacol 2003;17:483-490.
Ejskjaer N, Vestergaard ET, Hellstrom PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009;29:1179-1187.
Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther 2010;32:1221-1233.
Han C, Masand PS, Krulewicz S, et al. Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. J Clin Pharm Ther 2009;34:79-88.
Marks DM, Han C, Krulewicz S, et al. History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. Prim Care Companion J Clin Psychiatry 2008;10:368-375.
Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31.
Spiegel BM, Kanwal F, Naliboff B, et al. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol 2005;100:2262-2273.
Jones MP, Coppens E, Vos R, et al. A multidimensional model of psychobiological interactions in functional dyspepsia: a structural equation modelling approach. Gut 2013;62:1573-1580.

You must be logged in with a subscription to access this page. Click here to login.